Protalix BioTherapeutics (FRA:PBDA) Cyclically Adjusted Book per Share: €-1.26 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PBDA Protalix BioTherapeutics Inc FRA:PBDA
56 GF Score
Price €2.00
GF Value €1.89
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Cyclically Adjusted Book per Share?

Protalix BioTherapeutics FRA:PBDA +2.15% 56 Cyclically Adjusted Book per Share is €-1.26 as of Jun. 2026. GuruFocus rates FRA:PBDA with a GF Score™ of 56/100 and a GF Value™ of €1.89 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Protalix BioTherapeutics's adjusted book value per share for the three months ended in Jun. 2026 was €0.769. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-1.26 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 20.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 10.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Protalix BioTherapeutics was 20.30% per year. The lowest was -81.30% per year. And the median was -18.90% per year.

As of today (2026-08-19), Protalix BioTherapeutics's current stock price is €2.00. Protalix BioTherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €-1.26. Protalix BioTherapeutics's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Protalix BioTherapeutics was 90.67. The lowest was 5.45. And the median was 13.66.


Protalix BioTherapeutics  (FRA:PBDA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Protalix BioTherapeutics was 90.67. The lowest was 5.45. And the median was 13.66.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Protalix BioTherapeutics Cyclically Adjusted Book per Share Related Terms


Protalix BioTherapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Protalix BioTherapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protalix BioTherapeutics Cyclically Adjusted Book per Share Chart

Protalix BioTherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.30 -2.53 -2.49 -1.97 -1.22

Protalix BioTherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.42 -1.21 -1.22 -1.26 -1.26

FRA:PBDA vs GLSI, DTIL, NERV: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Protalix BioTherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:PBDA
56GF Score
Protalix BioTherapeutics Inc FRA:PBDA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protalix BioTherapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protalix BioTherapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.769/333.9520*333.9520
=0.769

Current CPI (Jun. 2026) = 333.9520.

Protalix BioTherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 -1.347 241.428 -1.863
201612 -0.760 241.432 -1.051
201703 -5.119 243.801 -7.012
201706 -1.425 244.955 -1.943
201709 -1.634 246.819 -2.211
201712 -1.732 246.524 -2.346
201803 -2.197 249.554 -2.940
201806 -2.864 251.989 -3.796
201809 -3.756 252.439 -4.969
201812 -3.133 251.233 -4.165
201903 -3.570 254.202 -4.690
201906 -4.025 256.143 -5.248
201909 -4.336 256.759 -5.640
201912 -4.265 256.974 -5.543
202003 -0.861 258.115 -1.114
202006 -0.952 257.797 -1.233
202009 -0.848 260.280 -1.088
202012 -0.639 260.474 -0.819
202103 0.268 264.877 0.338
202106 0.070 271.696 0.086
202109 0.004 274.310 0.005
202112 -0.117 278.802 -0.140
202203 -0.147 287.504 -0.171
202206 -0.192 296.311 -0.216
202209 -0.232 296.808 -0.261
202212 -0.187 296.797 -0.210
202303 0.015 301.836 0.017
202306 0.503 305.109 0.551
202309 0.491 307.789 0.533
202312 0.422 306.746 0.459
202403 0.375 312.332 0.401
202406 0.362 314.175 0.385
202409 0.397 315.301 0.420
202412 0.544 315.605 0.576
202503 0.535 319.799 0.559
202506 0.543 322.561 0.562
202509 0.561 324.800 0.577
202512 0.512 324.054 0.528
202603 0.722 330.213 0.730
202606 0.769 333.952 0.769

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-1.26 mean?
Protalix BioTherapeutics (FRA:PBDA) has a Cyclically Adjusted Book per Share of €-1.26 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Protalix BioTherapeutics and its competitors.
Is Protalix BioTherapeutics' Cyclically Adjusted Book per Share too high?
Protalix BioTherapeutics' current Cyclically Adjusted Book per Share is €-1.26. Overall, Protalix BioTherapeutics has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Cyclically Adjusted Book per Share compare to GLSI and DTIL?
Protalix BioTherapeutics' Cyclically Adjusted Book per Share of €-1.26 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Protalix BioTherapeutics and its competitors. Protalix BioTherapeutics's current Cyclically Adjusted Book per Share is €-1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (FRA:PBDA) is currently considered Fairly Valued. The stock's GF Value™ is €1.89, compared to a current price of €2.00 — trading 5.8% above its estimated fair value. The current Cyclically Adjusted Book per Share is €-1.26. Protalix BioTherapeutics' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Protalix BioTherapeutics (FRA:PBDA), the current Cyclically Adjusted Book per Share is €-1.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protalix BioTherapeutics (FRA:PBDA) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of €2.00 is trading 5.8% above its estimated GF Value™ of €1.89. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for FRA:PBDA:

  • Cyclically Adjusted Book per Share: €-1.26
  • GF Value™: €1.89 vs. price of €2.00 (5.8% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:PBDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Protalix BioTherapeutics Business Description

Other Exchanges PLX:USA
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
56GF Score

Get the complete analysis for FRA:PBDA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price
€1.89
GF Value